Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of RYZ801 to give with RYZ811 in people with inoperable liver cancer. Inoperable means the cancer cannot be taken out with surgery. The people in this study have hepatocellular carcinoma (HCC) that makes high levels of a liver protein called GPC3.
Researchers want to learn if giving ivosidenib with other drugs is safe and works well in people with advanced cholangiocarcinoma. The people in this study have cholangiocarcinoma that has metastasized (spread) and is inoperable (cannot be removed with surgery). Their tumors have a mutation (change) in the IDH1 gene.
In this study, researchers want to find the best doses of 2 different drug combinations. This study is for people with acute myeloid leukemia (AML) that keeps growing even after treatment. You also must have changes (mutations or variants) in the FLT3 gene, and in either the IDH1 or IDH2 genes. The FLT3 gene can cause cancer cells to grow. The IDH1 and IDH2 genes cause low blood cell counts.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.
Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body's normal blood cell production.
Researchers want to find the best dose of ziftomenib to give with imatinib in people with advanced gastrointestinal stromal tumors (GIST). The people in this study have GIST that keeps growing after treatment.
Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:
